Promising first Phase III data for Takeda's fasiglifam
This article was originally published in Scrip
Executive Summary
Takeda has released the first Phase III results for its novel antidiabetic fasiglifam (TAK-875), which show promising signs of efficacy for the first-in-class oral GPR40 agonist in a first-line setting.